The results showed that MSI gastric cancer constituted 13.4% of the cases (n = 13); MSS/EMT gastric tumors represented 29.9% of the cases (n = 29); MSS/p53- tumors counted 34% of the cases (n = 33) and MSS/p53+ represented 22.7% of the cases (n = 22). This evidence concerns the gene TP53 and gastric neoplasm.